Nicox completes enrollment in NCX 470 trial

Enrollment is complete in a phase 2 clinical trial of NCX 470, Nicox’s second-generation nitric oxide-donating bimatoprost analog, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release.

The multicenter, double-masked, 28-day, parallel group, dose response study is comparing NCX 470 ophthalmic solution with latanoprost ophthalmic solution 0.005%. Its primary endpoint is a mean reduction in diurnal IOP after 28 days, with a main objective of identifying an appropriate dose of NCX 470 to advance to phase 3 studies, the release said.

“We look forward to announcing the topline results of this first efficacy phase 2 study of NCX 470, which we believe has the potential to be a new best-in-class treatment for the reduction of intraocular pressure in glaucoma patients in the U.S. and worldwide,” Michele Garufi, Nicox chairman and CEO, said in the release. “The timely execution of this study demonstrates that we are continuing to deliver on our strategy across our entire portfolio of product candidates in development.”Topline results are expected in the fourth quarter.

Enrollment is complete in a phase 2 clinical trial of NCX 470, Nicox’s second-generation nitric oxide-donating bimatoprost analog, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release.

The multicenter, double-masked, 28-day, parallel group, dose response study is comparing NCX 470 ophthalmic solution with latanoprost ophthalmic solution 0.005%. Its primary endpoint is a mean reduction in diurnal IOP after 28 days, with a main objective of identifying an appropriate dose of NCX 470 to advance to phase 3 studies, the release said.

“We look forward to announcing the topline results of this first efficacy phase 2 study of NCX 470, which we believe has the potential to be a new best-in-class treatment for the reduction of intraocular pressure in glaucoma patients in the U.S. and worldwide,” Michele Garufi, Nicox chairman and CEO, said in the release. “The timely execution of this study demonstrates that we are continuing to deliver on our strategy across our entire portfolio of product candidates in development.”Topline results are expected in the fourth quarter.